STAT

FDA approves first new drug developed for women with postpartum depression

The FDA approved Sage Therapeutics' brexanolone, the first drug specifically targeted to treat postpartum depression.

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important

You're reading a preview, sign up to read more.

More from STAT

STAT1 min read
Listen: The Latest On The China Virus, Sarepta’s Ongoing FDA Saga, And Biotech At Davos
Are we dealing with a SARS redux? Has the FDA lost its teeth? And what do billionaires talk to each other about? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Helen Branswell joins us
STAT3 min readSociety
New Coronavirus Can Cause Infections With No Symptoms And Sicken Otherwise Healthy People, Studies Show
The new coronavirus can cause infections without any symptoms, and it can sicken otherwise healthy individuals, according to two of the first rigorous analyses of patients who contracted it.
STAT4 min read
WHO Declines To Declare China Virus Outbreak A Global Health Emergency
The WHO declared the ongoing outbreak of a novel virus a global health emergency, a move that reflects the widespread nature of the threat posed by the pathogen.